Sanofi - Aventis Groupe: Press Release: Nirsevimab delivers

Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab's consistent and high efficacy against infant hospitalizations

Related Keywords

China , Lisbon , Lisboa , Portugal , Canada , Philadelphia , Pennsylvania , United States , Japan , United Kingdom , Paris , France General , France , Corentine Driancourt , Pthomas Triomphe , Nicolas Obrist , Sandrine Guendoul , Nathalie Pham , Sally Bain , Evan Berland , Eva Schaefer Jansen , Simon Drysdale , Tarik Elgoutni , Felix Lauscher , National Medical Products Administration , European Medicines Agency Ema Priority , Nasdaq , Astrazeneca , Regulatory Agency , Drug Administration , Japan Agency For Medical Research , European Union , George University Hospital , China Center , Euronext , Burden Of Community , Vice President , Infectious Diseases , University Hospital , Co Chief Investigator , Antibody Prevention , Breakthrough Therapy Designation , Drug Evaluation , European Medicines Agency , Promising Innovative Medicine , United Kingdom Medicines , Drug Selection , Promote New Drug Development , Japan Agency , Medical Research , Business Operating , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Annual Meeting , European Society , Paediatric Infectious Diseases , Young Children , Global Level , Systematic Review , Syncytial Virus Bronchiolitis , Gefallene Big Techs , Sanofi , Eventis , Roupe , Dress , Release , Nirsevimab , Elivers , Reduction , Infant , Hospitalizations , Meal , World , Linical , Trial , Setting ,